A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas Meeting Abstract

  

Authors:	Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Abstract Title:	A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas
Meeting Title:	44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	26
Issue:	15 Suppl.
Meeting Dates:	2008 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2008-05-20
Start Page:	457s
Language:	English
ACCESSION:	WOS:000208457403158
DOI:	10.1200/jco.2008.26.15_suppl.8512
PROVIDER:	wos
Notes:	Meeting Abstract: 8512 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129869